Cargando…

Considerations regarding current diagnosis and prognosis of hepatocellular carcinoma

Hepatocellular carcinoma is a major health issue, ranked the fifth most common tumor and currently being responsible for a third of the cancer-related deaths globally, with an ever-increasing number of fatalities. Current advances in contrast-enhanced imaging techniques such as contrast-enhanced ult...

Descripción completa

Detalles Bibliográficos
Autores principales: Cristea, CG, Gheonea, IA, Săndulescu, LD, Gheonea, DI, Ciurea, T, Purcarea, MR
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Carol Davila University Press 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4392085/
https://www.ncbi.nlm.nih.gov/pubmed/25866565
_version_ 1782365920214122496
author Cristea, CG
Gheonea, IA
Săndulescu, LD
Gheonea, DI
Ciurea, T
Purcarea, MR
author_facet Cristea, CG
Gheonea, IA
Săndulescu, LD
Gheonea, DI
Ciurea, T
Purcarea, MR
author_sort Cristea, CG
collection PubMed
description Hepatocellular carcinoma is a major health issue, ranked the fifth most common tumor and currently being responsible for a third of the cancer-related deaths globally, with an ever-increasing number of fatalities. Current advances in contrast-enhanced imaging techniques such as contrast-enhanced ultrasonography, multi-detector computed tomography and diffusion-weighted magnetic resonance imaging are improving the rate of hepatocellular carcinoma diagnosis. Contrast-enhanced ultrasonography has widely become the first choice in liver tumor assessment, as it is faster, simpler and safer than other forms of diagnostic imaging. On the other hand, cross sectional computed tomography is frequently employed when a hepatic formation is suspected of malignancy and allows a more accurate characterization of lesions through multiphasic multi-detector computed tomography technology. Diffusion weighted magnetic resonance imaging represents another addition to the wide range of diagnostic and prognostic techniques available for patients with hepatocellular carcinoma and is currently regarded as one of the best tools for the characterization of these lesions. Furthermore, groundbreaking biomarkers for hepatocellular carcinoma are being discovered, although alpha-fetoprotein remains one of the most frequently used serum test in the early stages. Nonetheless, further advances are required for the detection of small liver carcinomas. Abbreviations : AASLD = American Association for the Study of Liver Diseases, AFP = Alpha-fetoprotein, AFP-L3 = Alpha-fetoprotein isoform 3, CEUS = Contrast-enhanced ultrasonography, DCP = Des-gamma-carboxy-prothrombin, DW-MRI = Diffusion weighted magnetic resonance imaging, FNA = Fine neddle aspiration, Gd-EOB-DTPA = Gadolinium ethoxybenzyl diethylenetriaminepentaacetic acid, GGT-II = Gamma-glutamyl transpeptidase II, GP73 = Golgi protein 73, HCC = Hepatocellular carcinoma, HCCR-1 = Human cervical cancer proto-oncogene 1, IL-18 = Interleukin 18, MDCT = Multi-detector computed tomography, PET-CT = Positron emission tomography – computed tomography, SUV = Standardized Uptake Value
format Online
Article
Text
id pubmed-4392085
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Carol Davila University Press
record_format MEDLINE/PubMed
spelling pubmed-43920852015-06-01 Considerations regarding current diagnosis and prognosis of hepatocellular carcinoma Cristea, CG Gheonea, IA Săndulescu, LD Gheonea, DI Ciurea, T Purcarea, MR J Med Life Reviews Hepatocellular carcinoma is a major health issue, ranked the fifth most common tumor and currently being responsible for a third of the cancer-related deaths globally, with an ever-increasing number of fatalities. Current advances in contrast-enhanced imaging techniques such as contrast-enhanced ultrasonography, multi-detector computed tomography and diffusion-weighted magnetic resonance imaging are improving the rate of hepatocellular carcinoma diagnosis. Contrast-enhanced ultrasonography has widely become the first choice in liver tumor assessment, as it is faster, simpler and safer than other forms of diagnostic imaging. On the other hand, cross sectional computed tomography is frequently employed when a hepatic formation is suspected of malignancy and allows a more accurate characterization of lesions through multiphasic multi-detector computed tomography technology. Diffusion weighted magnetic resonance imaging represents another addition to the wide range of diagnostic and prognostic techniques available for patients with hepatocellular carcinoma and is currently regarded as one of the best tools for the characterization of these lesions. Furthermore, groundbreaking biomarkers for hepatocellular carcinoma are being discovered, although alpha-fetoprotein remains one of the most frequently used serum test in the early stages. Nonetheless, further advances are required for the detection of small liver carcinomas. Abbreviations : AASLD = American Association for the Study of Liver Diseases, AFP = Alpha-fetoprotein, AFP-L3 = Alpha-fetoprotein isoform 3, CEUS = Contrast-enhanced ultrasonography, DCP = Des-gamma-carboxy-prothrombin, DW-MRI = Diffusion weighted magnetic resonance imaging, FNA = Fine neddle aspiration, Gd-EOB-DTPA = Gadolinium ethoxybenzyl diethylenetriaminepentaacetic acid, GGT-II = Gamma-glutamyl transpeptidase II, GP73 = Golgi protein 73, HCC = Hepatocellular carcinoma, HCCR-1 = Human cervical cancer proto-oncogene 1, IL-18 = Interleukin 18, MDCT = Multi-detector computed tomography, PET-CT = Positron emission tomography – computed tomography, SUV = Standardized Uptake Value Carol Davila University Press 2015 /pmc/articles/PMC4392085/ /pubmed/25866565 Text en ©Carol Davila University Press http://creativecommons.org/licenses/by/2.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Reviews
Cristea, CG
Gheonea, IA
Săndulescu, LD
Gheonea, DI
Ciurea, T
Purcarea, MR
Considerations regarding current diagnosis and prognosis of hepatocellular carcinoma
title Considerations regarding current diagnosis and prognosis of hepatocellular carcinoma
title_full Considerations regarding current diagnosis and prognosis of hepatocellular carcinoma
title_fullStr Considerations regarding current diagnosis and prognosis of hepatocellular carcinoma
title_full_unstemmed Considerations regarding current diagnosis and prognosis of hepatocellular carcinoma
title_short Considerations regarding current diagnosis and prognosis of hepatocellular carcinoma
title_sort considerations regarding current diagnosis and prognosis of hepatocellular carcinoma
topic Reviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4392085/
https://www.ncbi.nlm.nih.gov/pubmed/25866565
work_keys_str_mv AT cristeacg considerationsregardingcurrentdiagnosisandprognosisofhepatocellularcarcinoma
AT gheoneaia considerationsregardingcurrentdiagnosisandprognosisofhepatocellularcarcinoma
AT sandulesculd considerationsregardingcurrentdiagnosisandprognosisofhepatocellularcarcinoma
AT gheoneadi considerationsregardingcurrentdiagnosisandprognosisofhepatocellularcarcinoma
AT ciureat considerationsregardingcurrentdiagnosisandprognosisofhepatocellularcarcinoma
AT purcareamr considerationsregardingcurrentdiagnosisandprognosisofhepatocellularcarcinoma